Search for European Projects

4 European Projects Found

Searched on 125080 European Projects

 FINISHED 

Molecularly guided trials with specific treatment strategies in patients with advanced newly molecular defined subtypes of colorectal cancer (MoTriColor) (MoTriColor)

Start date: Oct 1, 2015, End date: Sep 30, 2019,

Colorectal cancer (CRC) is increasingly being recognized as a heterogeneous disease with distinct molecular subtypes. These subtypes have different biological processes at the basis of their disease and consequently their prognosis and responses to therapy are also different.We have previously developed molecular diagnostic assays using a single platform on routine FFPE tumour biopsies. These assa ...
Read Project

 12

 FINISHED 

Improved breast cancer care by innovative diagnostic test MammaPrint (MammaPrint)

Start date: Jul 1, 2015, End date: Jun 30, 2017,

Agendia NV, a Dutch SME, was founded in 2003 as spin-off from the Netherlands Cancer Institute. They pursue the commercialization of molecular diagnostics using DNA microarray technology for cancer. Agendia aims to be one of the key market players in genomic breast cancer profiling. One of the products Agendia is developing is MammaPrint, a breast cancer recurrence test. This test identifies the r ...
Read Project

 1

 FINISHED 

Rational Therapy for Breast Cancer: Individualized Treatment for Difficult-to-Treat Breast Cancer Subtypes (RATHER)

Start date: Jan 1, 2011, End date: Dec 31, 2016,

"Cancer genotyping has identified a number of correlations between mutations in specific genes and responses to targeted anti-cancer drugs, with many mutations occurring in kinases or downstream signaling components. While there are several ongoing large-scale genome re-sequencing studies for the major cancer types, there is no systematic effort to investigate kinase mutations in distinct biologic ...
Read Project

 8

 FINISHED 

Modelling and predicting sensitivity to targeted therapies in colorectal cancers (COLTHERES)

Start date: Jan 1, 2011, End date: Dec 31, 2014,

Effective and long term treatment of cancer is now in sight, but will ultimately require an increasingly ‘personalised’ approach where the ‘right’ combination of drugs will be administered to the ‘right’ patients, based on a detailed understanding of their genetic background and their co-associated sensitivity or resistance ‘biomarkers’. Efforts are specifically required to identify validated risk ...
Read Project

 11